PTGS2 and breast cancer: Cohesive scientific evidence from molecular, animal, and human investigations supports the hypothesis that overexpression of cyclooxygenase-2 drives mammary carcinogenesis and, reciprocally, that blockade of the inflammatory cyclooxygenase–prostaglandin cascade has strong potential for breast cancer prevention and therapy (2).